These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1043 related items for PubMed ID: 22051730

  • 1. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Mar; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
    Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S.
    Blood; 2013 Nov 28; 122(23):3784-6. PubMed ID: 24068492
    [Abstract] [Full Text] [Related]

  • 12. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Nov 28; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST, Gotlib J.
    Expert Rev Hematol; 2010 Jun 28; 3(3):323-37. PubMed ID: 21082983
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boiocchi L, Vener C, Savi F, Bonoldi E, Moro A, Fracchiolla NS, Iurlo A, Deliliers GL, Coggi G, Bosari S, Gianelli U.
    J Clin Pathol; 2011 Mar 28; 64(3):226-31. PubMed ID: 21217153
    [Abstract] [Full Text] [Related]

  • 18. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 28; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 19. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.
    Int J Hematol; 2007 Aug 28; 86(2):130-6. PubMed ID: 17875526
    [Abstract] [Full Text] [Related]

  • 20. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 28; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.